IL112088A - Stable stem cell factor formulations with improved stability and methods for their production - Google Patents

Stable stem cell factor formulations with improved stability and methods for their production

Info

Publication number
IL112088A
IL112088A IL11208894A IL11208894A IL112088A IL 112088 A IL112088 A IL 112088A IL 11208894 A IL11208894 A IL 11208894A IL 11208894 A IL11208894 A IL 11208894A IL 112088 A IL112088 A IL 112088A
Authority
IL
Israel
Prior art keywords
scf
formulations
formulation
lyophilized
sucrose
Prior art date
Application number
IL11208894A
Other languages
English (en)
Other versions
IL112088A0 (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL112088A0 publication Critical patent/IL112088A0/xx
Publication of IL112088A publication Critical patent/IL112088A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11208894A 1993-12-22 1994-12-20 Stable stem cell factor formulations with improved stability and methods for their production IL112088A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/172,507 US6288030B1 (en) 1993-12-22 1993-12-22 Stem cell factor formulations and methods

Publications (2)

Publication Number Publication Date
IL112088A0 IL112088A0 (en) 1995-03-15
IL112088A true IL112088A (en) 2001-04-30

Family

ID=22627993

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11208894A IL112088A (en) 1993-12-22 1994-12-20 Stable stem cell factor formulations with improved stability and methods for their production

Country Status (13)

Country Link
US (4) US6288030B1 (de)
EP (1) EP0732935B1 (de)
CN (1) CN1105575C (de)
AT (1) ATE173402T1 (de)
AU (1) AU696860B2 (de)
CA (1) CA2182970C (de)
DE (1) DE69414723T2 (de)
DK (1) DK0732935T3 (de)
ES (1) ES2123951T3 (de)
IL (1) IL112088A (de)
NZ (1) NZ278252A (de)
WO (1) WO1995017206A1 (de)
ZA (1) ZA9410189B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6472208B1 (en) * 1999-12-13 2002-10-29 Héma-Québec Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
MXPA03005014A (es) * 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3963786B2 (ja) * 2002-06-11 2007-08-22 富士通株式会社 情報処理装置
AU2003298775B2 (en) * 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
BRPI0417186A (pt) * 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
EP1957633B1 (de) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunmodulation unter verwendung von plazentastammzellen
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
NZ606814A (en) 2006-10-23 2014-10-31 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
CN103356710A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
KR20200136051A (ko) * 2007-09-26 2020-12-04 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
EP2203176B1 (de) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumorsuppression mit menschlichem plazentaperfusat und menschlichen natürlichen killerzellen eines zwischenproduktes aus der plazenta
AU2008325142A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
NZ591292A (en) * 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
SI2331109T1 (sl) * 2008-08-22 2013-10-30 Anthrogenesis Corporation Postopki in sestavki za zdravljenje okvar kosti s populacijami placentarnih celic
WO2010059828A1 (en) 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
EP2375907B1 (de) * 2008-11-21 2019-02-27 Celularity, Inc. Behandlung von krankheiten, störungen oder leiden der lunge mittels plazentazellen
EP2449095A1 (de) * 2009-07-02 2012-05-09 Anthrogenesis Corporation Verfahren zur produktion von erythrozyten ohne feederzellen
CA2787992A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
EP3622960A1 (de) 2013-02-05 2020-03-18 Celularity, Inc. Natürliche killerzellen aus plazenta
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS5534001A (en) * 1978-08-28 1980-03-10 Noda Sangyo Kagaku Kenkyusho Stabilization of sarcosine oxidase
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS5874617A (ja) 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第7因子含有水溶液の加熱処理方法
JPS58134991A (ja) * 1981-12-28 1983-08-11 Takeda Chem Ind Ltd セラチオペプチタ−ゼの安定化法
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第8因子の加熱処理法
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ226170A (en) 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
ATE108326T1 (de) 1989-01-30 1994-07-15 Corint Ltd Wässerige desmopressin-cmc enthaltende arzneizubereitung.
JPH02268681A (ja) * 1989-04-07 1990-11-02 Green Cross Corp:The ウロキナーゼ前駆体の安定化方法及び乾燥製剤
CA2028848A1 (en) * 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
EP0676470A1 (de) 1989-10-16 1995-10-11 Amgen Inc. Stammzellenfaktor
HUT62011A (en) 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
EP0536317A1 (de) 1990-06-25 1993-04-14 Immunex Corporation Wachstumsfaktor der mastzellen
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Also Published As

Publication number Publication date
DE69414723D1 (de) 1998-12-24
US6020469A (en) 2000-02-01
CN1105575C (zh) 2003-04-16
US20020013258A1 (en) 2002-01-31
EP0732935A1 (de) 1996-09-25
ZA9410189B (en) 1995-08-25
NZ278252A (en) 1998-04-27
DE69414723T2 (de) 1999-07-22
AU1442295A (en) 1995-07-10
ES2123951T3 (es) 1999-01-16
HK1008815A1 (en) 1999-05-21
US6288030B1 (en) 2001-09-11
US5965522A (en) 1999-10-12
IL112088A0 (en) 1995-03-15
CA2182970A1 (en) 1995-06-29
EP0732935B1 (de) 1998-11-18
CN1142771A (zh) 1997-02-12
DK0732935T3 (da) 1999-08-02
WO1995017206A1 (en) 1995-06-29
CA2182970C (en) 2000-11-28
ATE173402T1 (de) 1998-12-15
AU696860B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
AU696860B2 (en) Lyophilized stem cell factor formulations
CA2079780C (en) Methods and formulations for stabilizing fibroblast growth factor
BRPI0002276B1 (pt) Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou composição e processso para a preparação de compostos
EP0910399B1 (de) Stabilisierte pharmazeutische zusammensetzung von bdnf
WO1990000397A1 (en) A pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
EP1496926B1 (de) Verwendung von transthyretin-peptid/protein-fusionen zur verlängerung der serumhalbwertszeit von pharmakologisch wirksamen peptiden/proteinen
EP0787497A2 (de) Humanes Wachstumshormon enthaltendes pharmazeutisches Präparat
CN113274486A (zh) 一种稳定的酸性成纤维细胞生长因子制剂及其制备方法和应用
EP1827483B1 (de) Therapeutische formulierungen von keratinozyten-wachstumsfaktor
EP0904367B1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
MXPA00005214A (es) Una jeringa de una dosis, que comprende una composicion de proteina liofilizada, para administrar un volumen menor de 0.5 ml.
HK1008815B (en) Lyophilized stem cell factor formulations
JPH0327320A (ja) ヒトb細胞分化因子医薬組成物
AU598300B2 (en) Succinylated interleukin-2 for pharmaceutical compositions
JPH101439A (ja) 神経変性疾患治療剤
EP0557319B1 (de) Therapeutische verwendung des fibroblastenwachstumsfaktors
CN113663132B (zh) 脂肪组织再生水凝胶及其制备方法和应用
EP0494664A1 (de) Menschliche bFGF-Derivate, deren Analoga und Verfahren zu deren Herstellung
JPH0378847B2 (de)
RU2664192C1 (ru) Рекомбинантный ген, кодирующий белок hbd-epo, рекомбинантная плазмидная днк pl610, способ получения рекомбинантного белка hbd-epo, рекомбинантный белок hbd-epo, композиция для специфической индукции регенерации костной ткани, способ специфической индукции регенерации костной ткани
HK40056899A (en) Adipose tissue regeneration hydrogel, preparation method thereof, and use thereof
AU738891B2 (en) Stable transglutaminase preparations and process for producing them
JPH0418031A (ja) 損傷治癒促進剤
JPH01193231A (ja) 抗腫瘍剤
JPH08259459A (ja) 巨核球増殖分化剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees